ATOSSA THERAPEUTICS, INC.

For the period ended Mar 31, 2025. Filed May 13, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Mar 31, 2025 · Filed May 13, 2025

ATOS$2.14+0.5%Stored close · as of Nov 10, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Condensed Consolidated Statements of Cash Flows

(amounts in thousands)

	For the Three Months Ended March 31,
	2025	2024
CASH FLOWS FROM OPERATING ACTIVITIES
Net loss	$(6,718)	$(5,878)
Adjustments to reconcile net loss to net cash used in operating activities
Stock-based compensation	563	417
Loss on disposal of assets	—	2
Depreciation	4	5
Changes in operating assets and liabilities:
Prepaid materials	19	115
Prepaid expenses and other current assets	(274)	549
Other assets	(11)	—
Accounts payable	486	424
Accrued expenses	869	640
Payroll liabilities	(920)	(995)
Other current liabilities	23	23
Net cash used in operating activities	(5,959)	(4,698)
CASH FLOWS FROM INVESTING ACTIVITIES
Purchases of property and equipment	(9)	(6)
Net cash used in investing activities	(9)	(6)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from exercise of warrants	—	204
Net cash provided by financing activities	—	204
NET DECREASE IN CASH, CASH EQUIVALENTS AND RESTRICTED CASH	(5,968)	(4,500)
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, BEGINNING BALANCE	71,194	88,570
CASH, CASH EQUIVALENTS AND RESTRICTED CASH, ENDING BALANCE	$65,226	$84,070
RECONCILIATION OF CASH AND CASH EQUIVALENTS AND RESTRICTED CASH
Cash and cash equivalents	$65,116	$83,960
Restricted cash	110	110
Total cash, cash equivalents and restricted cash	$65,226	$84,070

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.